ATE530916T1 - Verfahren zur vorhersage des ansprechens auf eine pharmazeutische therapie der fettsucht - Google Patents

Verfahren zur vorhersage des ansprechens auf eine pharmazeutische therapie der fettsucht

Info

Publication number
ATE530916T1
ATE530916T1 AT08867898T AT08867898T ATE530916T1 AT E530916 T1 ATE530916 T1 AT E530916T1 AT 08867898 T AT08867898 T AT 08867898T AT 08867898 T AT08867898 T AT 08867898T AT E530916 T1 ATE530916 T1 AT E530916T1
Authority
AT
Austria
Prior art keywords
obesity
pharmaceutical agent
pharmaceutical therapy
biomarker
predicting responses
Prior art date
Application number
AT08867898T
Other languages
English (en)
Inventor
Jennifer Leohr
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40386209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE530916(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE530916T1 publication Critical patent/ATE530916T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT08867898T 2007-12-19 2008-12-18 Verfahren zur vorhersage des ansprechens auf eine pharmazeutische therapie der fettsucht ATE530916T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1488107P 2007-12-19 2007-12-19
PCT/US2008/087367 WO2009085917A1 (en) 2007-12-19 2008-12-18 Method for predicting responsiveness to a pharmaceutical therapy for obesity

Publications (1)

Publication Number Publication Date
ATE530916T1 true ATE530916T1 (de) 2011-11-15

Family

ID=40386209

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08867898T ATE530916T1 (de) 2007-12-19 2008-12-18 Verfahren zur vorhersage des ansprechens auf eine pharmazeutische therapie der fettsucht

Country Status (17)

Country Link
US (2) US8084261B2 (de)
EP (2) EP2235544A1 (de)
JP (1) JP5242701B2 (de)
KR (2) KR20100088624A (de)
AT (1) ATE530916T1 (de)
AU (2) AU2008343177B2 (de)
BR (2) BRPI0821364A2 (de)
CA (2) CA2710248A1 (de)
CY (1) CY1112352T1 (de)
DK (1) DK2238458T3 (de)
ES (1) ES2373625T3 (de)
HR (1) HRP20110840T1 (de)
MX (1) MX2010006890A (de)
PL (1) PL2238458T3 (de)
PT (1) PT2238458E (de)
SI (1) SI2238458T1 (de)
WO (2) WO2009085917A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2517268T3 (es) * 2009-07-22 2014-11-03 Eli Lilly And Company Procedimiento para predecir el aumento de peso asociado a una terapia farmacéutica
WO2014204990A2 (en) * 2013-06-18 2014-12-24 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Methods of predicting of chemical properties from spectroscopic data
WO2016065463A1 (en) * 2014-10-28 2016-05-06 2352409 Ontario Inc. Methods for providing personalized diet and activity recommendations that adapt to the metabolism of each dieter individually using frequent measurements of activity and triglyceride levels
KR102397234B1 (ko) 2020-09-17 2022-05-12 가천대학교 산학협력산 약물 순응도 평가 방법 및 시스템

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003450A1 (en) * 1991-07-30 1993-02-18 North Carolina State University Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
FR2767135B1 (fr) * 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
AU2054000A (en) * 1999-02-26 2000-09-14 Lipomed, Inc. Methods, systems, and computer program products for analyzing and presenting risk assessment results based on nmr lipoprotein analysis of blood
WO2003012416A1 (en) * 2001-08-01 2003-02-13 Liposcience, Inc. Method of determining presence and concentration of lipoprotein x in blood plasma and serum
CA2477614A1 (en) * 2002-03-05 2003-09-18 Merck & Co., Inc. Biomarker for efficacy of appetite suppressant drugs
CA2561536C (en) 2004-04-01 2017-09-19 Liposcience, Inc. Nmr clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation of biosamples
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
EP1876448A1 (de) * 2005-09-30 2008-01-09 DIGILAB BioVisioN GmbH Verfahren und analytische Reagenzien zur Medikamentidentifizierung mittels auf Thiazolidinedionen reagierenden Biomarkern

Also Published As

Publication number Publication date
KR101240875B1 (ko) 2013-03-08
US8084261B2 (en) 2011-12-27
CA2710248A1 (en) 2009-07-09
JP5242701B2 (ja) 2013-07-24
PL2238458T3 (pl) 2012-03-30
DK2238458T3 (da) 2012-01-23
US20100268474A1 (en) 2010-10-21
WO2009085917A1 (en) 2009-07-09
KR20100084577A (ko) 2010-07-26
AU2008343177A1 (en) 2009-07-09
EP2238458A1 (de) 2010-10-13
US8355877B2 (en) 2013-01-15
CA2710395C (en) 2016-10-18
AU2008343177B2 (en) 2013-09-26
US20100248375A1 (en) 2010-09-30
EP2238458B1 (de) 2011-10-26
EP2235544A1 (de) 2010-10-06
MX2010006890A (es) 2010-09-30
ES2373625T3 (es) 2012-02-07
PT2238458E (pt) 2012-01-11
CA2710395A1 (en) 2009-07-09
JP2011508218A (ja) 2011-03-10
HRP20110840T1 (hr) 2011-12-31
BRPI0821364A2 (pt) 2015-06-16
SI2238458T1 (sl) 2012-02-29
WO2009085927A1 (en) 2009-07-09
CY1112352T1 (el) 2015-12-09
BRPI0821051A2 (pt) 2015-06-16
BRPI0821051B1 (pt) 2022-02-08
AU2008343187A1 (en) 2009-07-09
KR20100088624A (ko) 2010-08-09

Similar Documents

Publication Publication Date Title
NO20084615L (no) Fremgangsmåte og apparat for å bestemme om et medikament vil være effektivt eller ikke for en pasient med en sykdom
BR112015015131A2 (pt) método, aparelho, mídia de armazenamento não transitório, programa de computador, e produto
MX2012001716A (es) Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf.
BRPI0915300C1 (pt) compostos de éster boronato e composições farmacêuticas dos mesmos
DE602005025106D1 (de) Methoden zur medikamentenaufspürung auf der basis von in vitro differenzierten zellen
BR112012011646A2 (pt) sistema de teste de aptidão fisica e produto de programa de computador
WO2012058609A3 (en) Method and apparatus for selecting a tracking method to use in image guided treatment
BR112012016463A2 (pt) método e aparelho para medir a eficácia de extermínio de um desinfetante.
BR112014030569A2 (pt) método de monitoramento da função pulmonar de um paciente; produto de programa de computador; e sistema para uso no monitoramento da função pulmonar de um paciente
DE112006003722A5 (de) Simulationssystem für chirurgische Eingriffe in der Human- und Veterinärmedizin
BR112012024813A8 (pt) método e sistema para mostrar dados de sensor de analito
BRPI0916174A2 (pt) "sistema de exibição, método e produto de programa de computador"
EP2272519A4 (de) Verfahren und pharmazeutische zusammensetzung zur erreichung der plasma-progesteronspiegel, die für verschiedene therapeutische indikationen notwendig sind
BRPI0818741A2 (pt) equipamento e método de avaliação da presença de microorganismos no sangue
BRPI0813926A2 (pt) Utilização de uma substância, composição e métodos de triagem de princípios ativos que inibem a formação dos ages e de cuidado cosmético.
ATE530916T1 (de) Verfahren zur vorhersage des ansprechens auf eine pharmazeutische therapie der fettsucht
BR112012019044A2 (pt) método de processamento de exibição de componente e equipamento de usuário
EP2513336A4 (de) Verfahren zur bestimmung der immunfunktion eines wirtes durch ex-vivo-einführung offensiver und defensiver immunmarker
BRPI0820514A2 (pt) Método para detectar um nível baixo de tinta e produto de computador para detectar um evento de fim-de-vida"
BRPI0814119A2 (pt) Método de análise de diafragma e uso dos produtos obtidos de acordo com o método
BR112012026224A2 (pt) métodos para tratar mal de alzheimer e para avaliar a eficácia de uma terapia
BR112014029808A2 (pt) método para testar o efeito de uma etapa de produção ou etapas de produção ou a eficácia de uma etapa de purificação ou etapas de purificação na presença ou na natureza de moléculas pró-inflamatórias em polímeros de glicose ou hidrolisados dos mesmos; e método otimizado para produzir ou purificar polímeros de glicose ou hidrolisados dos mesmos
DE112010000122A5 (de) Verfahren und vorrichtung zum messen der aktivität von enzymen nach inhibitorentzug
FR2931613B1 (fr) Dispositif et procede de verification d'integrite d'objets physiques
ATE499040T1 (de) Vorrichtung zur arzneimittelverabreichung und/oder überwachung des zustandes eines patienten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2238458

Country of ref document: EP